Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma

PURPOSE: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that the observed synergy is due to the role of HDAC6 in mediating resistance to proteasome inhibition via the aggresome/autoph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Principais autores: Vogl, Dan T., Raje, Noopur, Jagannath, Sundar, Richardson, Paul, Hari, Parameswaran, Orlowski, Robert, Supko, Jeffrey G., Tamang, David, Yang, Min, Jones, Simon S., Wheeler, Catherine, Markelewicz, Robert J., Lonial, Sagar
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5496796/
https://ncbi.nlm.nih.gov/pubmed/28053023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados